Creating a unit to evaluate vaccines and treatments for infectious diseases at NYU.
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)
['FUNDING_OTHER'] · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · NIH-11223660
The NYU Vaccine and Treatment Evaluation Unit is looking for people to help test new vaccines and treatments for infectious diseases like Ebola and Zika, so we can better protect everyone’s health.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11223660 on ClinicalTrials.gov |
What this research studies
The NYU Vaccine and Treatment Evaluation Unit (VTEU) aims to conduct clinical trials focused on developing innovative vaccines and treatments for infectious diseases. This unit will collaborate with the National Institute of Allergy and Infectious Diseases (NIAID) and other research centers to address emerging health threats like Ebola, Zika, and antibiotic resistance. Patients may participate in trials that test new medical countermeasures, contributing to the advancement of public health. The research will also focus on improving existing vaccines and developing new ones for diseases like tuberculosis and AIDS.
Who could benefit from this research
Good fit: Ideal candidates for participation include individuals at risk for or affected by infectious diseases, including those with compromised immune systems.
Not a fit: Patients with non-infectious diseases or those not at risk for the targeted infectious diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines and treatments for serious infectious diseases, ultimately improving patient outcomes.
How similar studies have performed: Previous research has shown success in developing vaccines and treatments through similar evaluation units, indicating a promising approach.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MULLIGAN, MARK JOSEPH — NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- Study coordinator: MULLIGAN, MARK JOSEPH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome, Airway infections